Cancer最新文献

{"title":"Reply to “De-escalation of axillary surgery in patients with sentinel lymph node micrometastases after neoadjuvant systemic therapy”","authors":"Dong Seung Shin MD, Jai Min Ryu MD, PhD, Se Kyung Lee MD, PhD, Jonghan Yu MD, PhD, Jeong Eon Lee MD, PhD, Seok Won Kim MD, PhD, Seok Jin Nam MD, PhD, Byung Joo Chae MD, PhD","doi":"10.1002/cncr.35699","DOIUrl":"10.1002/cncr.35699","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De-escalation of axillary surgery in patients with sentinel lymph node micrometastases after neoadjuvant systemic therapy","authors":"Mariam Rizk MD, Kefah Mokbel MBBS, MS, FRCS","doi":"10.1002/cncr.35698","DOIUrl":"10.1002/cncr.35698","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A national estimate of mental disorders and mortality outcomes in cancer survivors","authors":"Thi Xuan Mai Tran PhD,&nbsp;Min Sung Chung MD, PhD,&nbsp;Chihwan Cha MD,&nbsp;Boyoung Park MD, PhD","doi":"10.1002/cncr.35711","DOIUrl":"10.1002/cncr.35711","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study evaluated the prevalence of various mental disorders and their influence on mortality outcomes in individuals with cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The authors' institutional database included patients with cancer diagnosed between 2011 and 2015 who had mental disorders and death information up to 2021. Mental disorders included nonaffective psychotic disorders, affective psychotic disorders, anxiety-related and stress-related disorders, alcohol or drug misuse, and mood disorders without psychotic symptoms. The causes of death were classified as all-cause, cancer-related, or suicide. Individual matching was performed to randomly match cancer survivors with and without mental disorders according to age at cancer diagnosis, year of cancer diagnosis, sex, and cancer site. The association between mental disorders and mortality risk was assessed using a Cox proportional hazards model and competing-risk analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 637,491 cancer survivors (mean age, 58.9 years), there were 238,654 deaths from any cause and 2255 deaths from suicide. Incidence rates varied across disorders, with the highest rates observed for anxiety-related and stress-related disorders and mood disorders without psychotic symptoms. Mental disorders were associated with an increased risk of all-cause and cancer-related mortality. Adjusted hazard ratios (HRs) for nonaffective psychotic disorders, affective psychotic disorders, anxiety-related and stress-related disorders, alcohol and drug misuse, and mood disorders without psychotic symptoms were as follows: HR, 2.49 (95% confidence interval [CI], 2.22–2.80); HR, 2.38 (95% CI, 2.21–2.57); HR, 1.02 (95% CI, 1.01–1.04); HR, 2.13 (95% CI, 1.87–2.43); and HR, 1.27 (95% CI, 1.24–1.30), respectively, for all-cause mortality. Suicide risk was higher in patients who had mental disorders, especially within the first 6 months after diagnosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The current findings underscore the impact of mental illness on mortality among cancer survivors in Korea, specifically highlighting the elevated rates of anxiety, stress, and mood disorders.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of female-specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021","authors":"Wenhui Ren PhD,&nbsp;Xiangyu Guo MM,&nbsp;Zheng Liu MPH,&nbsp;Yanqiu Wu MEng,&nbsp;Rui Peng MM,&nbsp;Huixin Liu PhD,&nbsp;Jinlei Qi PhD","doi":"10.1002/cncr.35712","DOIUrl":"10.1002/cncr.35712","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Breast cancer and reproductive system cancers remain significant public health threats for Chinese women. This study aimed to evaluate the latest epidemiological patterns and trends of four female-specific cancers in China.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The year- and age-specific estimates of the incidence, mortality, and disability-adjusted life-years (DALYs) associated with breast, cervical, ovarian, and uterine cancers in China from 1990 to 2021 were generated from the Global Burden of Disease, Injuries, and Risk Factors 2021 study. The epidemiological characteristics were analyzed with age–period–cohort models. A Bayesian age–period–cohort model was applied to forecast disease burden from 2022 to 2050.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In 2021, China reported 385.84 thousand (95% uncertainty interval [UI], 294.10–489.01 thousand) incident cases of female breast cancer, followed by cervical cancer (132.79 thousand [95% UI, 95.96–172.60 thousand]), uterine cancer (72.02 thousand [95% UI, 53.31–100.00 thousand]), and ovarian cancer (41.24 thousand [95% UI, 30.30–54.55 thousand]). Breast cancer ranked as the primary cause of cancer-related deaths, followed by cervical cancer. The age-specific incidence rate for breast, cervical, ovarian, and uterine cancers are projected to occur in the age groups 60–64 years, 55–59 years, 65–69 years, and 60–64 years, respectively. Breast, ovarian, and uterine cancer cases are projected to rise by 2050, which will exceed those recorded in 2021.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Various inequities have been identified across four types of cancers affecting women, which underscores the need for tailored national cancer control strategies. Emphasis should be placed on primary prevention and screening for breast and cervical cancers, whereas efforts for uterine and ovarian cancers should focus on implementing early diagnosis and treatment measures.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Plain language summary&lt;/h3&gt;\u0000 \u0000 &lt;div&gt;\u0000 \u0000 &lt;ul&gt;\u0000 \u0000 &lt;li&gt;\u0000 \u0000 &lt;p&gt;This study examines the burdens and trends of breast, cervical, ovarian, and uterine cancers among Chinese women from 1990 to 2021.&lt;/p&gt;\u0000 &lt;/li&gt;\u0000 \u0000 &lt;li&gt;\u0000 \u0000 &lt;p&gt;In 2021, breast cancer emer","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a-rearranged acute myeloid leukemia","authors":"Lulu Wang MD,&nbsp;Yuxiu Chen MD,&nbsp;Mengtong Zang MD,&nbsp;Jianying Zhou MD,&nbsp;Mengyu Xiao MD,&nbsp;Haixia Fu PhD,&nbsp;Xiaodong Mo PhD,&nbsp;Fengrong Wang PhD,&nbsp;Wei Han PhD,&nbsp;Yuanyuan Zhang PhD,&nbsp;Chenhua Yan PhD,&nbsp;Zhidong Wang PhD,&nbsp;Tingting Han PhD,&nbsp;Meng Lv PhD,&nbsp;Huan Chen PhD,&nbsp;Yuhong Chen PhD,&nbsp;Yao Chen PhD,&nbsp;Jingzhi Wang PhD,&nbsp;Yu Wang PhD,&nbsp;Lanping Xu PhD,&nbsp;Kaiyan Liu PhD,&nbsp;Xiaojun Huang PhD,&nbsp;Xiaohui Zhang PhD","doi":"10.1002/cncr.35717","DOIUrl":"10.1002/cncr.35717","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients with lysine methyltransferase 2a (<i>KMT2A</i>)-rearranged (<i>KMT2A</i>-r) acute myeloid leukemia (AML) are assigned to intermediate-risk and adverse-risk categories at diagnosis. However, the value of molecular measurable residual disease (MRD) status in patients who have <i>KMT2A</i>-r AML before allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult cohorts has rarely been evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with <i>KMT2A</i>-r AML who achieved complete remission and subsequently underwent allo-HSCT between January 2015 and January 2023 were included in this analysis. Real-time quantitative polymerase chain reaction was used to detect molecular MRD in bone marrow samples. The end points were overall survival (OS), leukemia-free survival (LFS), the cumulative incidence of relapse (CIR), and nonrelapse mortality (NRM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Pretransplantation molecular MRD was identified in 52 of 125 patients (42%) with <i>KMT2A</i>-r AML. The presence of <i>KMT2A</i>-r MRD was associated with inferior 3-year OS (51% vs. 82%; <i>p</i> &lt; .001), LFS (42% vs. 81%; <i>p</i> &lt; .001), CIR (33% vs. 12%; <i>p</i> &lt; .001), and NRM (11% vs. 5%; <i>p</i> = .12). In multivariate models, molecular MRD status before transplantation independently predicted OS, LFS, and CIR. The survival of adult patients with <i>KMT2A</i>-r AML was heterogeneous, depending on the <i>KMT2A</i> translocation partners, and was more favorable in patients who had t(9;11) and t(10;11) than in those who had t(11;19) and t(6;11). In addition, flow cytometry-based MRD analysis conferred no additional prognostic value to the results of molecular MRD status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Residual <i>KMT2A</i>-r before allo-HSCT independently predicts the risk of survival and relapse, and donor lymphocyte infusion or posttransplantation maintenance therapies should be considered for patients who have AML with detectable molecular MRD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial/ethnic differences in trends of testicular germ cell tumor incidence in the United States, 1992–2021","authors":"Andrea A. Almeida MA, MPH,&nbsp;Aika Wojt MS,&nbsp;Catherine Metayer PhD, MD,&nbsp;Peter A. Kanetsky PhD, MPH,&nbsp;Barry I. Graubard PhD,&nbsp;Christian S. Alvarez PhD, MPH,&nbsp;Katherine A. McGlynn PhD, MPH","doi":"10.1002/cncr.35706","DOIUrl":"10.1002/cncr.35706","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Testicular germ cell tumors (TGCTs) are the most common cancers among young men in the United States. Incidence rates among non-Hispanic White (NHW) men historically have been much higher than the rates among other men. To study whether this pattern had changed, the authors examined trends in TGCT incidence for the years 1992–2021.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>By using the Surveillance, Epidemiology, and End Results 12 registries database, age-standardized incidence rates per 100,000 person-years and 95% confidence intervals (CIs) were calculated overall and by histologic type (seminoma and nonseminoma), age, stage at diagnosis, and race/ethnicity. Trends in 5-year survival also were examined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The age-standardized incidence rate of TGCT per 100,000 person-years increased from 4.71 (95% CI, 4.39–5.05) in 1992 to 6.22 (95% CI, 5.88–6.58) in 2021. The rates increased for both seminoma (average annual percent change [AAPC], 0.57%; 95% CI, 0.40%–0.75%) and nonseminoma (AAPC, 1.41%; 95% CI, 1.17%–1.64%) and among all race/ethnic groups, although the rates stabilized among NHW men. Increases in incidence were greatest among Hispanic men (AAPC, 3.03%; 95% CI, 2.66%–3.40%), who had one of the youngest median ages at diagnosis and were more likely to be diagnosed at advanced stages compared with NHW men. Seminoma and nonseminoma rates among Hispanic men converged over the study period, whereas seminoma rates remained higher among most other groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Hispanic men now have the highest TGCT incidence rates in the United States, although the rates increased among all groups between 1992 and 2021. Racial/ethnic differences in rates require further investigation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35706","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A trial of radiolabeled antibody yttrium-90–FF-21101 for the treatment of advanced ovarian and other cancers","authors":"Devalingam Mahalingam MD, PhD,&nbsp;Taofeek K. Owonikoko MD, PhD,&nbsp;Ebrahim Delpassand MD, PhD,&nbsp;Mary F. Mulcahy MD,&nbsp;Aparna Kalyan MD,&nbsp;Susanna Ulahannan MD,&nbsp;Kin Cheung PhD,&nbsp;Yasayuki Izumi MEng,&nbsp;Mary Johansen PharmD,&nbsp;Timothy Madden PharmD,&nbsp;Susumu Shimoyama MS,&nbsp;Ruth Ann Subach PharmD,&nbsp;Takeaki Suzuki PhD,&nbsp;David S. Wages MD, PhD,&nbsp;Catherine Wheeler MD,&nbsp;Debra L. Richardson MD","doi":"10.1002/cncr.35680","DOIUrl":"10.1002/cncr.35680","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Yttrium-90 FF-21101 (⁹⁰Y–FF-21101) is a radiopharmaceutical that targets P-cadherin as a therapy against solid tumors. A previously reported, first-in-human study determined that a dose of 25 mCi/m² was safe, and a patient with clear cell carcinoma of the ovary achieved a complete response. In this article, the authors report the results of ⁹⁰Y–FF-21101 treatment in an ovarian carcinoma expansion cohort and in patients with selected solid tumors who had known high P-cadherin expression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The trial was conducted as an open-label study in patients with advanced/metastatic disease. Radiologic response and safety were evaluated in patients who received 25 mCi/m² intravenously once every three cycles of 28 days until they developed progressive disease. Evaluation of the ovarian cohort was conducted in a Simon two-stage manner to determine further enrollment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifty-seven patients (20 with ovarian carcinoma) were enrolled and treated. Patients who had ovarian and solid tumors had received a median of five and three prior therapies, respectively. No complete or partial responses were observed, so the trial was ended. The median progression-free survival was 118 days for the ovarian cohort and 55 days for the solid-tumor cohort. The most common treatment-related adverse events were thrombocytopenia (40%) and neutropenia (54%). One patient each developed fatal veno-occlusive disease and intracranial hemorrhage. Patients with higher P-cadherin levels remained on the study longer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>⁹⁰Y–FF-21101 did not meet the predefined efficacy criteria, and adverse events were consistent with ⁹⁰Y agents. These data may assist in the development of other P-cadherin–directed therapies (ClinicalTrials.gov identifier NCT02454010).</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142918672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From childhood cancer to metabolic syndrome","authors":"Aman Wadhwa MD, MPSH","doi":"10.1002/cncr.35682","DOIUrl":"10.1002/cncr.35682","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142918712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of a cancer screening program using multicancer early detection testing and whole-body magnetic resonance imaging in a high-risk population","authors":"Dan J. Raz MD,&nbsp;Bita Nehoray MS, CGC,&nbsp;Aaron Ceniceros BS,&nbsp;Pejman Motarjem MD,&nbsp;Shana Landau MD,&nbsp;Rebecca A. Nelson PhD,&nbsp;Stacy W. Gray MD","doi":"10.1002/cncr.35709","DOIUrl":"10.1002/cncr.35709","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The authors assessed the feasibility, acceptability, and impact on cancer worry of a cancer screening program using multicancer early detection (MCED) tests and whole-body magnetic resonance imaging (WBM) in individuals at high cancer risk because of family history or germline variants in cancer-susceptibility genes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective trial enrolled participants aged 50 years and older who had a significant family history of cancer or a cancer-susceptibility gene variant. Participants underwent noncontrast WBM and MCED testing. The results were shared with participants, and further imaging or consultations were conducted as needed. Surveys assessing anxiety, cancer worry, and acceptability of the intervention were completed at baseline and 6 months after testing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>One hundred participants were enrolled: 98 completed both WBM and MCED testing, and 89 completed their 6-month follow-up. The median age of participants was 62 years (range, 51–83 years), and 64% were women. Four participants (4%) were diagnosed with cancer based on WBM findings and subsequent work-up, and all four underwent surgical resection. Two intraductal papillary mucinous neoplasms of the pancreas were detected and are being monitored. MCED testing was positive in four participants, none of whom had suspicious findings on magnetic resonance imaging. One participant with a JAK2 mutation and thrombocytosis is under monitoring for potential hematologic malignancy. Sixty-two participants (85%) somewhat/strongly agreed that study participation reduced cancer worry. Composite Cancer Worry Scale scores demonstrated decreased worry at 6 months compared with baseline (51% vs. high worry in 69%; <i>p</i> &lt; .001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>MCED and WBM testing were feasible, acceptable, and were associated with decreased cancer worry at 6 months (clinical trials registration: NCT05868486).</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142918709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective study on diagnostic accuracy of technology-enabled early detection of oral cancer and epidemiology of tobacco and other substances use in rural India","authors":"Divya Khanna MD,&nbsp;Aseem Mishra MCh,&nbsp;Praveen Birur MDS,&nbsp;Tulika Shruti MDS,&nbsp;Keerthi Gurushanth MDS,&nbsp;Nirza Mukhia MDS,&nbsp;Ruchi Pathak DGO,&nbsp;Arjun Gurmeet Singh MDS,&nbsp;Anupama Shetty PhD,&nbsp;Satyajit Pradhan MD,&nbsp;Pankaj Chaturvedi MS","doi":"10.1002/cncr.35702","DOIUrl":"10.1002/cncr.35702","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lip and oral cavity cancer is leading cause of cancer mortality among Indian men. This study evaluated diagnostic accuracy of mobile health (mHealth) enabled screening for early detection of oral premalignant lesions or oral cancer (OPML/OC). It also described epidemiology of tobacco and other substance use and associated oral lesions in rural northern India.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A prospective study enrolled 10,101 high-risk individuals from rural settings of Varanasi district, India, between February 2021 and June 2023. Trained field workers captured habits information and oral cavity images and provided screening as suspicious or nonsuspicious on mHealth. Onsite experts and remote specialists provided clinical diagnoses. Diagnostic accuracy of mHealth-enabled screening was evaluated. A subset of 252 participants was followed to assess changes in oral lesions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Prevalence of substance use was 55.7%, with 21.4% having OPML/OC. Sensitivity of field workers and remote diagnosis for detecting OPML/OC was moderate when compared with onsite expert. Overall, interobserver agreement was substantial. During follow-up, the remote specialists identified 30 new and 13 progressive lesions with a significant decline in the red mean parameter of red, green, and blue colour ratios.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Although mHealth-enabled screening demonstrated lower sensitivity in detecting OPML/OC, their high specificity and expanded access to screening positions mHealth as a valuable tool for improving oral cancer screening coverage in Varanasi. This is particularly crucial given the high burden of oral cancer driven by prevalent smokeless tobacco and areca nut use and the current lack of effective population-based screening programs in this region.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142918729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}